GC 2107

Drug Profile

GC 2107

Alternative Names: CB02-0133; GC-2107; GC4401; GCC-2107; GCC-4401; GCC-4401C; I Fxa - LegoChem Biosciences; LCB-02-0133; Nokxaban

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LegoChem Biosciences
  • Developer GC Pharma; LegoChem Biosciences
  • Class Anticoagulants; Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Embolism; Stroke; Venous thromboembolism

Most Recent Events

  • 13 Feb 2018 GC 2107 licensed to Lee Pharmaceuticals in China and South East Asia
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Embolism(Prevention, In volunteers) in USA (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke(Prevention, In volunteers) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top